EA201891026A1 - Лечение опухолей центральной нервной системы - Google Patents

Лечение опухолей центральной нервной системы

Info

Publication number
EA201891026A1
EA201891026A1 EA201891026A EA201891026A EA201891026A1 EA 201891026 A1 EA201891026 A1 EA 201891026A1 EA 201891026 A EA201891026 A EA 201891026A EA 201891026 A EA201891026 A EA 201891026A EA 201891026 A1 EA201891026 A1 EA 201891026A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
central nervous
specifically
rna interference
present
Prior art date
Application number
EA201891026A
Other languages
English (en)
Other versions
EA038254B1 (ru
Inventor
Стивен Де Влеешоувер
Маттиас Ван Военсель
Карим Амигхи
Натали Ваутхоз
Реми Розьер
Original Assignee
Католике Университет Лёвен
Университе Либре Де Брюссель
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Католике Университет Лёвен, Университе Либре Де Брюссель filed Critical Католике Университет Лёвен
Publication of EA201891026A1 publication Critical patent/EA201891026A1/ru
Publication of EA038254B1 publication Critical patent/EA038254B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение в общем относится к новому составу, содержащему наночастицы, инкапсулирующие миРНК для применения технологии РНК-интерференции для сайленсинга гена галектина-1, вовлеченного в прогрессирование опухоли. Более конкретно настоящее изобретение относится к применению молекул РНК-интерференции для лечения злокачественной опухоли центральной нервной системы, более конкретно для лечения мультиформной глиобластомы (GBM).
EA201891026A 2015-11-23 2016-11-23 Лечение опухолей центральной нервной системы EA038254B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520600.6A GB201520600D0 (en) 2015-11-23 2015-11-23 Treatment of central nervous tumours
PCT/EP2016/078547 WO2017089392A1 (en) 2015-11-23 2016-11-23 Treatment of central nervous tumours

Publications (2)

Publication Number Publication Date
EA201891026A1 true EA201891026A1 (ru) 2018-12-28
EA038254B1 EA038254B1 (ru) 2021-07-30

Family

ID=55133198

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891026A EA038254B1 (ru) 2015-11-23 2016-11-23 Лечение опухолей центральной нервной системы

Country Status (10)

Country Link
US (1) US11007154B2 (ru)
EP (1) EP3380087B1 (ru)
JP (1) JP7076103B2 (ru)
CN (1) CN108472265A (ru)
AU (1) AU2016358718B2 (ru)
BR (1) BR112018010292A2 (ru)
CA (1) CA3005992C (ru)
EA (1) EA038254B1 (ru)
GB (1) GB201520600D0 (ru)
WO (1) WO2017089392A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110396524B (zh) * 2019-05-31 2023-05-02 海南大学 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途
CN112716971B (zh) * 2021-01-19 2022-01-25 苏州大学 lncRNA XR_595534.2在制备治疗或预防慢性疼痛的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604288C (en) * 2005-04-12 2021-07-06 Universite Libre De Bruxelles Use of a galectin-1-targeted rnai-based approach for the treatment of cancer
WO2009006905A1 (en) 2007-07-06 2009-01-15 Aarhus Universitet Dehydrated chitosan nanoparticles
CA2820236C (en) 2012-06-15 2022-07-19 The Royal Institution For The Advancement Of Learning/Mcgill University Non-viral nanoparticle-based delivery system

Also Published As

Publication number Publication date
US20180344658A1 (en) 2018-12-06
CN108472265A (zh) 2018-08-31
US11007154B2 (en) 2021-05-18
EP3380087B1 (en) 2022-06-08
EA038254B1 (ru) 2021-07-30
AU2016358718B2 (en) 2022-08-18
CA3005992A1 (en) 2017-06-01
BR112018010292A2 (pt) 2018-11-27
JP7076103B2 (ja) 2022-05-27
GB201520600D0 (en) 2016-01-06
CA3005992C (en) 2024-01-02
EP3380087A1 (en) 2018-10-03
AU2016358718A1 (en) 2018-06-07
JP2018534339A (ja) 2018-11-22
WO2017089392A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12019501959A1 (en) Therapeutic rna
WO2016106406A3 (en) Rna agents for gst-pi gene modulation
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
EA202191009A1 (ru) Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k
EA201400178A1 (ru) Лечение рака молочной железы
CY1124006T1 (el) Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
PH12017501879A1 (en) Methods for treating cancer
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
TW201613949A (en) Targeting microRNAs for metabolic disorders
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
EA201891026A1 (ru) Лечение опухолей центральной нервной системы
MX2017009608A (es) Compuestos anticancerigenos.
GB2507700A (en) Compositions and methods for treatment of metastatic cancer
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
WO2013103836A3 (en) Methods of treating cancer
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
DK3725810T3 (da) Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer